DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Vera Therapeutics - 3 Vera - 3 Sarah Min - 2 Robinhood - 1 Berenberg - 1 DoorDash - 1 Alex Harring - 1 Jefferies - 1
Top related locs:
Vera Albemarle ph.II billings Macao America Caribbean Wells Fargo
Top related orgs:
LSEG - 1 Revenue - 1 Nike — - 1 Bank of America - 1 Citi - 1 Constellation - 1 Modelo - 1 Constellation Brands - 1

Search resuls for: "Vera Therapeutics"


4 mentions found


☆ Stocks making the biggest premarket moves: Nike, CarMax, Robinhood, Alpine Immune Sciences and more
  + stars: | 2024-04-11 | by ( Michelle Fox | ) www.cnbc.com   time to read: +2 min
Nike — Shares added 2% following an upgrade at Bank of America to buy from neutral. Alpine Immune Sciences — Shares of Alpine Immune Sciences soared nearly 37% after Vertex Pharmaceuticals said it will buy the company for about $4.9 billion in cash. The deal values Alpine stock at $65, about 67% above its close on Tuesday, the day before Bloomberg reported Alpine was considering its options. Vera Therapeutics — The stock jumped more than 10% following the announcement of the Vertex/Alpine deal. Atlassian — Shares jumped 4% after being upgraded at Barclays to overweight from equal weight.
Persons: Robinhood, Vera Therapeutics, Berenberg, DoorDash, Alex Harring, Sarah Min Organizations: LSEG, Revenue, Nike —, Bank of America, Citi, Constellation, Modelo, Constellation Brands, Immune Sciences, Vertex Pharmaceuticals, Bloomberg, Barclays, CNBC Locations: Vera, Albemarle
☆ Jefferies upgrades this little-known biotech stock with more than 100% upside
  + stars: | 2023-11-10 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
The firm upgraded shares of the late-stage biotech to buy from hold, lifting its price target to $26 from $18. Shares of Vera Therapeutics have fallen 37.8% this year, but analyst Farzin Haque believes the stock's recent pullback now means an attractive entry point for investors. VERA YTD mountain VERA YTD chart "W/ shares down –30% (vs XBI –13%) since Sept 21 TVTX data release, we have become more optimistic about atacicept (dual BAFF/APRIL) clin profile," Haque wrote. Atacicept, which Vera took over from Merck, is a drug that treats certain autoimmune diseases. "W/ recent increasing focus on eGFR, VERA's OLE data from ph.II for longer-term eGFR data (expected 1Q24) has now become an important catalyst for the stock," Haque said.
Persons: Vera, Jefferies, Vera Therapeutics, Farzin Haque, VERA YTD, VERA, Haque, Lupus nephritis, — CNBC's Michael Bloom Organizations: Vera, Merck Locations: ph.II
☆ Stocks making the biggest moves midday: Groupon, Wynn Resorts, Plug Power, Illumina and more
  + stars: | 2023-11-10 | by ( Alex Harring | ) www.cnbc.com   time to read: +4 min
Wynn Resorts — The resort-and-casino stock dropped 7.3% as analysts focused on EBITDAR, which includes restructuring, tied to its operations in Macao. Plug Power — Shares of the clean energy company tumbled more than 34%, reaching a new 52-week low, after third-quarter earnings and revenue missed analysts' estimates. TKO Group — The WWE parent slid 7.9% after Executive Chairman Vince McMahon said he planned to sell 8.4 million shares. Treace Medical Concepts — Shares tumbled 40% after the medical device company missed third-quarter expectations and lowered its full-year revenue guidance. The company also cut revenue guidance for the year.
Persons: Vince McMahon, Treace, Freyr, Wells, Synaptics, LSEG, Vera Therapeutics, Vera, —, Sarah Min, Hakyung Kim, Pia Singh Organizations: Wynn Resorts, Diageo —, Diageo, RBC, JPMorgan, WWE, Wall, Analysts, Jefferies Locations: billings, Macao, America, Caribbean, Wells Fargo, Hawaii
☆ Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease
  + stars: | 2023-06-12 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States
0 next >>
Total: 4